Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Nov 04, 2021 11:42am
109 Views
Post# 34087031

RE:$3.50

RE:$3.50The volume is very low. It is wait and see on both sides. We all wait for the same thing: oncology results.

SPCEO1 wrote: The price of THTX is stuck at $3.50 and has been for several weeks now. This lack of movement, despite news of insider buying and the appointment of Dr. Rothenberg as well as interst in TH's SORT1+ platform and a huge bull run in the market is not a normal situation and one wonders what forces are at work that is leading to the stock flatlining at this level. 

I don't have any great explanations, unfortunately.

Could there be both a buyer and a seller of some size who both think $3.50 is the price they want to transact at and their respective algos are just working with each other over a number of weeks. Could Cantor be acquiring a position for later disposition at a profit when they put out a report complimentary of TH in preparation for the ATM offering?

Of course, we cannot really know what is going on, but it sure is odd.




<< Previous
Bullboard Posts
Next >>